Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU2008202130B2 - Anthelminthic formulation - Google Patents
[go: Go Back, main page]

AU2008202130B2 - Anthelminthic formulation - Google Patents

Anthelminthic formulation Download PDF

Info

Publication number
AU2008202130B2
AU2008202130B2 AU2008202130A AU2008202130A AU2008202130B2 AU 2008202130 B2 AU2008202130 B2 AU 2008202130B2 AU 2008202130 A AU2008202130 A AU 2008202130A AU 2008202130 A AU2008202130 A AU 2008202130A AU 2008202130 B2 AU2008202130 B2 AU 2008202130B2
Authority
AU
Australia
Prior art keywords
trichlorfon
sheep
medicament
formulation
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008202130A
Other versions
AU2008202130A1 (en
Inventor
Neil Fourie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Priority to AU2008202130A priority Critical patent/AU2008202130B2/en
Publication of AU2008202130A1 publication Critical patent/AU2008202130A1/en
Application granted granted Critical
Publication of AU2008202130B2 publication Critical patent/AU2008202130B2/en
Priority to AU2011200455A priority patent/AU2011200455A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

S&F Ref: 630384D1 AUSTRALIA PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT Name and Address Intervet International B.V., of Wim de Kcrvestratt 35, NL of Applicant: 5831, AN Boxmeer, The Netherlands Actual Inventor(s): Neil Fourie Address for Service: Spruson & Ferguson St Martins Tower Level 35 31 Market Street Sydney NSW 2000 (CCN 3710000177) Invention Title: Anthelminthic formulation The following statement is a full description of this invention, including the best method of performing it known to me/us: 5845c(1237644_1) I Anthelminthic formulation The present invention relates to a stable liquid formulation of an anthelminthic and more particularly to a formulation having an organophosphate e.g. trichlorfon as 5 active ingredient. Endoparasites commonly cause clinical disease in especially in livestock animals and have significant adverse economic effects on farming economies when present at subclinical levels. Anthelminthics, which control effectively important endoparasites, 10 but which offer improved human and environmental safety are a goal for animal production systems. An example of a endoparasite is Haemonchus contortus. Haemonchus contortus is a blood sucking parasite and the development of clinical signs are related to the loss of 15 whole blood. In acute infections, where large numbers of larvae are ingested over a period of days, anaemia can cause death. In chronic infections, where the rate of infection has been slower, both anaemia and hypoalbuminaemia result from the loss of whole blood and the exhaustion of erythropoietic reserves. 20 Organophosphates are generally effective against Haemonchus, Trichostrongylus, Cooperia, Oesophagostomum and Dictyocaulus in sheep. They are active against Haemonchus, Ostertagia, Trichostrongyus, Cooperia, Bunostomum and Oesophagostomum in cattle and against Gasterophilus (bots) in horses. Trichlorfon is an organophosphate used as an insecticide and pesticide for plants 25 and livestock as well as an anthelmintic for animals. The safety margin is very narrow, therefore exact dosing of the compound is necessary to avoid toxic reactions due to the application of higher dosages of trichlorfon. 30 One of the reasons for this is that the stable form of crystalline powder of trichlorfon breaks down in water if left for a relatively short period into the more toxic compound dichlorfos. The chemical stability of organophosphates such as trichlorfon is considerably impaired by the presence of water in formulations. It has been 35 established that trichlorfon re-arranges via dehydrochlorination to form dichlorfos 2 Thus the organophosphate such as trichlorfon had to be mixed on site for immediate use and all material not used had to be safely discarded. This resulted in a labour intensive preparation of the formulation that is to be applied to the animal and to higher costs for treatment and a need for safe discharge of not used material. 5 There has thus long been a need for a ready to use stable liquid solution of organophosphates such as trichlorfon and It Is the object of the present Invention to provide such a product. Trichlorfon (O,O-dimethyl-(2,2,2-trichloro-1-hydroxyethyl)-phosphonale dimethyl 2,2,2,2-trichloro-1-hydroxyethyl-phosphonate , also called metrifonate is an 0 organophosphorous compound having potent anticholinesterase activity and is administered topically as an ectoparasiticide or orally as an anthelmintic. Examples of other organophosphates as antiparasitic agents are e.g. dichlorvos, coumaphos, crufomate or haloxon. Organophosphates act as cholinesterase inhibitor by Irreversible inactivation of acetylcholinesterase, leading to excessive cholinergic 15 activity at relevant sites. In accordance with this invention there is provided the use of a ready to use stable liquid oral composition comprising trichlorfon dissolved in propylene glycol for the manufacture of a medicament for the treatment of wire worm infestations in 20 sheep. Glycol based solvents such as polyethylene glycol, glycerol formal and propylene glycol are able to dissolve the active compound and produce a stable formulation. Such formulation may also be dispersed in water. Although a carrier material such as propylene glycol is relatively expensive, the low cost and effective active Ingredient 25 make the product desirably priced in relation to overall results. The current invention further provides a process for preparing an anthelminthic formulation comprising the steps of dissolving the trichlorfon in the propylene glycol. In an example of this Invention crystalline trichlorfon is dissolved in propylene glycol in a ratio of twenty grams per 100 ml or 200 grams /11 resulting in a final 30 concentration of 20% m/v. The Invention further provides for a solution of trichlorfon In a glycol based solvent. The concentration of trichlorfon is between 10 and 30% w/v, preferably 15 -25 %. most preferred approximately 20% w/v solution. With approximately is meant that for a 20% solution the concentration may vary by one percent either way based on the total volume of the composition. This has been found to yield a stable solution over a considerable period of time. Trials (see Example 2) have shown a shelf life in excess of a year. 5 Optionally additional excipients such as colorants or thickening agents could be present in the composition according to the invention. Suitable pharmaceutical excipients are known in the art. Pharmaceutical excipients for oral liquid formulations are e.g. described in "Gennaro, Remington: The Science and Practice of Pharmacy" 10 (20th Edition, 2000), incorporated by reference herein. A still further feature of the invention provides the solution to include a distinctive colorant, which is of food quality. Preferably a food grade colorant (e.g. Eurocert Green S, EC No. E142, EC name Green S, supplier Warner Jenkinson) is added to 15 the solution to give it a distinctive easily recognizable identification cover. The composition and method of the invention may be used to treat a wide variety of endoparasites of animals. The particular amount of the anthelminthic formulation required for a particular 20 treatment will vary, depending upon the species, age and weight of the animal being treated, the particular parasite to be guarded against, or treated, as well as the specific organophosphate compound selected for the treatment, the route and the frequency of administration. Anthelminthics are frequently delivered to ruminants in the form of oral drenches directly into the rumen. 25 The solution can be used against various endoparasites but is particularly effective against wire worm (Haemonchus contortus) and nasal grub (Oestrus ovis) in sheep. This parasite has become difficult to control and tests have shown (see Example 3) that the solution is effective where other widely used endoparasitics have not. 30 For example a suitable dosage of trichlorfon for oral administration for sheep is in the range between 30 to 110 mg/kg bodyweight (bw), preferably 40 to 100 mg/kg body weight, more preferred 45 to 80 mg/kg bw and most preferred 50 to 60mg/kg bodyweight. 35 A further aspect of the invention is an oral drench formulation comprising a composition according to the invention. The oral drench formulation comprising the solution is supplied in pre-packed 5 quantities to meet demand and is at all times in a ready to use condition. The product can be orally administered to sheep in a metered manner using a dosing gun (so called "drenching") and excess material may be stored for use at a later time. The invention also provides a method of treating sheep against wire worm 10 (Haemonchus contortus) infestation by the administration of a stored ready to use oral drench formulation comprising the solution as defined above. In a further aspect the current invention concerns a method for treating or controlling endoparasites of an animal which includes orally applying to an animal a stable liquid 15 composition according to the invention at a rate of 2 ml to 5 ml / 10kg, preferably 2.5 to 4.0 ml of the animal's live weight. The method may be also be used to treat or control other endoparasites on a variety of animals including livestock animals as sheep, cattle, deer, goats, pigs, and 20 companion animals as horses, dogs and cats. In a further embodiment a composition according to the invention further comprises an additional anthelminthic compound e.g. ivermectin, abamectin, fenbendazole, levamisole, closantel, niclosamide, rafoxanide or mixtures thereof. 25 Example 1 Preparation of the solution 5 Trichlorfon 20.0 % m/ v Lime Green PBL 0517(Food Colourant) 0.0001 m/ v Propylene glycol BP to: 100 /v Preparation 10 a) Charge production tank with 70% of total batch size of propylene glycol b) Dissolve the trichlorfon into the propylene glycol while stirring the contents of the production tank vigorously with a suitable vortex mixer c) Dissolve the dye (lime green PBL 0517/ Eurocert Green S) into small proportion of the balance of the propylene glycol and add this solution to the production 15 tank. Mix well d) Make the batch to volume with propylene glycol and again mix well. Example 2 Stability test 20 The product of example 1 (3 production batches) were stored at accelerated conditions for at least 9 weeks as well as at room temperature for the first 9 weeks and thereafter at 30*C for the following 40 weeks. Results are shown in Table 1 below. 25 Table 1: Stability week Batch 1 Batch 1 Batch 2 Batch 2 Batch 3 Batch 3 room 44 0 C room 54*C room 44 0 C temp. temp. temp. 0 20.59 20.59 2 21.54 19.98 3 20.19 19.23 20.76 20.89 5 19.84 17.88 20.80 17.92 7 21.29 18.15 21.57 15.61 9 20.07 16.60 19.91 20.31 11 21.11 21.20 21.32 week Batch 1 Batch 1 Batch 2 Batch 2 Batch 3 Batch 3 -0 room 44 0 C room 54 0 C room 44'C temp. temp. temp. 13 19.85 20.78 20.37 15 21.88 19.51 19.86 17 19.98 20.16 20.34 19 20.47 20.45 20.40 21 20.40 19.62 19.88 23 20.12 19.95 20.40 25 20.53 20.41 21.00 27 19.86 19.64 20.48 29 20.13 18.98 20.14 33 19.06 18.96 19.61 37 19.44 18.87 19.70 41 18.91 18.76 20.27 45 19.19 18.49 20.40 49 19.28 17.13 19.43 53 18.48 16.57 19.67 57 18.14 16.51 19.41 61 18.03 19.99 75 15.42 17.72 79 11.27 14.30 All room temperature samples were placed on 30*C on week 13. 5 Example 3 Efficacy study The objective of the study was to evaluate the efficacy of trichlorfon 20% solution at various dose rates against anthelmintic susceptible adult and immature H. contortus (Onderstrepoort stain) in sheep. The study was conducted in two phases: 10 Immature phase: Sheep (n=13) were infected with 1000 L3 H. contortus larvae (onderstrepoort strain) per os on Days -11, -8, -5 and -3. One untreated sheep was slaughtered on Day 0 as larval viability control to confirm the viability of the larvae dosed and to assess the development of the larvae. Sheep (n=3) were treated on 15 Day 0 with trichlorfon (20% m/v) according to the invention at a dosage rate of 40 mg /kg bodyweight (bw), sheep (n=3), at 50 mg/kg bw, sheep (n=3) and at 60 mg/kg bw. Sheep (n=3) were left untreated serving as controls. All remaining sheep (n=12) were necropsied on Day +21 in order to allow the worms to develop to adults for easier worm recovery. Adult phase: Sheep (n=13) were infected with 1000 L3 H. contortus larvae 5 (onderstrepoort strain) per os on Days -21, -18, -15 and -12. One untreated sheep was slaughtered on Day 0 as larval viability control to confirm the viability of the larvae dosed and to assess the development of the larvae. Sheep (n=3) were treated on Day 0 with trichlorfon (20% m/v) according to the invention at a dosage rate of 40 mg /kg bodyweight (bw), sheep (n=3), at 50 mg/kg bw, sheep (n=3) and at 60 mg/kg 10 bw. Sheep (n=3) were left untreated serving as controls. All remaining sheep (n=12) were necropsied on Day +14 in order to allow the worms to develop to adults for easier worm recovery. Faecal Egg Counts (FEC) were performed on faeces collected from all sheep on the 15 days of necropsy according to the method of Viser and Malan. Worm recovery was achieved by washing the ingesta thoroughly from the abomasal mucosa under a steam of water into a bucket. In addition, for the immature phase and the two larval viability controls the mucosal surface was scraped from the abomasum with a glass slide, placed in digestion fluid. The larvae and adult nematodes recovered were 20 identified and counted. Percentage control (Faecal Egg Count Reduction Test) and percentage efficacy (Worm Burden Reduction) values were calculated based on the untreated control group. The results are summarized in Table 2. 25 Results: The test formulation was found to be more than 99% effective (arithmetic reduction in worm burdens) against adult H. contortus at all three dosage rates (i.e. 40, 50 and 60 mg/kg bw). The efficacy recorded against immature H. contortus increased from 80.56% 30 (arithmetic reduction in worm burdens) at a dosage rate of 40 mg/kg bw to 95.52% at a dosage rate of 60 mg/kg bw (arithmetic reduction in worm burdens). The percentage efficacy against immature worms was 91.08% (arithmetic reduction in worm burdens) at a dosage rate of 50 mg/kg bw.
-0 Table 2 Percentage control and percentage efficacy values obtained using the faecal egg count reduction test and worm recovery at necropsy respectively 5 Group Infection date Dose level Faecal egg Nematode mg/kg counts: recovery: percentage percentage control recovery A -1-,-5& -3 40 78.53 80.56 B -11,8, -5& -3 I50 88.64 91.08| _c -1,-8, -5& -3 60 90. 91 -95.52 E -21, -18, -15, &12 40 100.00 99.97 F -21, -18, -15, &12 50 99.79 99.79 G -21, -18, -15, &-12 60 100.00 100.00

Claims (8)

1. Use of a ready to use stable liquid oral composition comprising trichlorfon dissolved in propylene glycol for the manufacture of a medicament for the treatment of wire worm infestations in sheep. 5
2. The use according to claim I characterized in that the content of trichlorfon is between 10 and 30% weight / volume.
3. The use according to claim I characterized in that the content of trichlorfon is approximately 20% weight / volume.
4. The use according to claim 1 to 3 characterized in that the composition to additionally comprises a colorant.
5. The use according to claims I to 4 wherein the medicament is an oral drench formulation.
6. A use as defined in claim I which is substantially as herein described with reference to Example 1. 15
7. A method for treating sheep against wire worm infestation which comprises orally applying to the animal an effective amount of a medicament as defined in claims I to 6.
8. The method of claim 7 wherein the medicament is orally applied at a rate of 2.5 ml to 4.0 ml / 10 kg of the animal's live weight. 20 Dated 30 September, 2010 Intervet International B.V. Patent Attorneys for the Applicant/Nominated Person SPRUSON & FERGUSON
AU2008202130A 2002-04-04 2008-05-14 Anthelminthic formulation Ceased AU2008202130B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2008202130A AU2008202130B2 (en) 2002-04-04 2008-05-14 Anthelminthic formulation
AU2011200455A AU2011200455A1 (en) 2002-04-04 2011-02-03 Anthelminthic formulation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ZA2002/2621 2002-04-04
ZA200202621 2002-04-04
AU2003203465A AU2003203465B2 (en) 2002-04-04 2003-04-01 Anthelminthic Formulation
AU2008202130A AU2008202130B2 (en) 2002-04-04 2008-05-14 Anthelminthic formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2003203465A Division AU2003203465B2 (en) 2002-04-04 2003-04-01 Anthelminthic Formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011200455A Division AU2011200455A1 (en) 2002-04-04 2011-02-03 Anthelminthic formulation

Publications (2)

Publication Number Publication Date
AU2008202130A1 AU2008202130A1 (en) 2008-06-05
AU2008202130B2 true AU2008202130B2 (en) 2010-11-04

Family

ID=32869980

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2003203465A Withdrawn - After Issue AU2003203465B2 (en) 2002-04-04 2003-04-01 Anthelminthic Formulation
AU2008202130A Ceased AU2008202130B2 (en) 2002-04-04 2008-05-14 Anthelminthic formulation
AU2011200455A Abandoned AU2011200455A1 (en) 2002-04-04 2011-02-03 Anthelminthic formulation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2003203465A Withdrawn - After Issue AU2003203465B2 (en) 2002-04-04 2003-04-01 Anthelminthic Formulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2011200455A Abandoned AU2011200455A1 (en) 2002-04-04 2011-02-03 Anthelminthic formulation

Country Status (5)

Country Link
AR (1) AR039250A1 (en)
AU (3) AU2003203465B2 (en)
BR (1) BR0300872A (en)
NZ (1) NZ525112A (en)
ZA (1) ZA200302223B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067096A (en) * 1961-01-26 1962-12-04 American Home Prod Anthelmintic composition and method of destroying animal parasites utilizing said composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040299A (en) * 1998-10-23 2000-03-21 Griffin Llc Cold storage stabilized organophosphorus insecticide formulation and method of making same
US6342466B1 (en) * 1999-09-02 2002-01-29 Clariant Finance (Bvi) Limited Biodegradable solutions of biologically active compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067096A (en) * 1961-01-26 1962-12-04 American Home Prod Anthelmintic composition and method of destroying animal parasites utilizing said composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D1"Medikamentelle Therapie der Gasterophilos der Pferdes" Ribbeck et al, Wissenschaftliche Zeitschrift 1985, 34(5), 510-516. *

Also Published As

Publication number Publication date
BR0300872A (en) 2004-08-17
AR039250A1 (en) 2005-02-16
ZA200302223B (en) 2003-10-13
AU2008202130A1 (en) 2008-06-05
NZ525112A (en) 2004-08-27
AU2011200455A1 (en) 2011-02-24
AU2003203465A1 (en) 2003-10-23
AU2003203465B2 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
US5169846A (en) Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
IE69667B1 (en) Formulations comprising praziquantel and another anthelmintic
EA026947B1 (en) Pesticidal compositions comprising an isoxazoline active agent and methods of use thereof
AU695582B2 (en) Anthelmintic formulations
US10449179B2 (en) Stable veterinary anthelmintic formulations
CA2364742C (en) Anthelmintic composition
EP4076447B1 (en) Parasite control in ruminants
EP0616494A1 (en) 1- n-(halo-3-pyridylmethyl)]-n-methylamino-1-alkylamino-2-nitroethylene derivatives for use against fleas on pets
AU2008202130B2 (en) Anthelminthic formulation
US9198430B2 (en) Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation
HU206037B (en) Process for producing nonaqueous pharmaceutical compositions for external use
CA2622713C (en) Anthelmintic formulations
EP0354761B1 (en) Veterinary compositions for use against endoparasites, and their preparation
RU2112379C1 (en) Insectoacaricide preparation for struggle against ectoparasites in animals
Anderson et al. Intraruminal controlled release of cyromazine for the prevention of Lucilia cuprina myiasis in sheep
AU628671B2 (en) Non-aqueous micellar solutions of various drugs
Pfadt Mortality of nasal bots in sheep treated with systemic insecticides
AU2005201107B8 (en) Anthelmintic compositions
WO2008072987A2 (en) Veterinary formulation
KENNETH MELLANBY et al. THE TREATMENT OF SCABIES
AU2008201426A1 (en) Anthelmintic compositions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired